This study is testing Dronabinol, an oral medication, to see if it can help treat obstructive sleep apnea (OSA). OSA is a serious breathing problem during sleep. All participants will take Dronabinol for two weeks. Researchers will conduct sleep studies before and after treatment to measure how much the OSA has improved. The main goal is to see if Dronabinol reduces the number of times breathing stops or becomes very shallow during sleep (Apnea Hypopnea Index or AHI). This study is looking for adults aged 18 to 65 who have moderate to severe OSA (AHI between 15 and 50). You cannot participate if you use a CPAP machine for more than 4 hours a day for 30% of days in the last three months. The current status of this study is unclear, and it plans to enroll up to 120 participants.

Study design

This is an open-label study, meaning everyone knows they are receiving Dronabinol. It plans to enroll up to 120 participants.

What's involved

You would take oral Dronabinol for two weeks. Sleep studies will be conducted before and after this treatment period.

Compensation

Not stated in the trial record.

Follow-up

Your AHI will be measured at 2 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.